Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape
Respiratory syncytial virus is the second most common cause of infant mortality and a major
cause of morbidity and mortality in older adults (aged> 60 years). Efforts to develop a …
cause of morbidity and mortality in older adults (aged> 60 years). Efforts to develop a …
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
N Chaudhary, D Weissman… - Nature reviews Drug …, 2021 - nature.com
Over the past several decades, messenger RNA (mRNA) vaccines have progressed from a
scepticism-inducing idea to clinical reality. In 2020, the COVID-19 pandemic catalysed the …
scepticism-inducing idea to clinical reality. In 2020, the COVID-19 pandemic catalysed the …
Antibodies to combat viral infections: development strategies and progress
G Pantaleo, B Correia, C Fenwick, VS Joo… - Nature Reviews Drug …, 2022 - nature.com
Monoclonal antibodies (mAbs) are appealing as potential therapeutics and prophylactics for
viral infections owing to characteristics such as their high specificity and their ability to …
viral infections owing to characteristics such as their high specificity and their ability to …
Respiratory syncytial virus infection and novel interventions
AC Langedijk, LJ Bont - Nature Reviews Microbiology, 2023 - nature.com
The large global burden of respiratory syncytial virus (RSV) respiratory tract infections in
young children and older adults has gained increased recognition in recent years. Recent …
young children and older adults has gained increased recognition in recent years. Recent …
Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity
INTRODUCTION Variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) have been circulating worldwide since the beginning of the pandemic. Some are termed …
2) have been circulating worldwide since the beginning of the pandemic. Some are termed …
Structure-based design of prefusion-stabilized SARS-CoV-2 spikes
The coronavirus disease 2019 (COVID-19) pandemic has led to accelerated efforts to
develop therapeutics and vaccines. A key target of these efforts is the spike (S) protein …
develop therapeutics and vaccines. A key target of these efforts is the spike (S) protein …
Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses
R Bos, L Rutten, JEM van der Lubbe, MJG Bakkers… - npj Vaccines, 2020 - nature.com
Abstract Development of effective preventative interventions against SARS-CoV-2, the
etiologic agent of COVID-19 is urgently needed. The viral surface spike (S) protein of SARS …
etiologic agent of COVID-19 is urgently needed. The viral surface spike (S) protein of SARS …
[HTML][HTML] D614G mutation alters SARS-CoV-2 spike conformation and enhances protease cleavage at the S1/S2 junction
The severe acute respiratory coronavirus 2 (SARS-CoV-2) spike (S) protein is the target of
vaccine design efforts to end the coronavirus disease 2019 (COVID-19) pandemic. Despite …
vaccine design efforts to end the coronavirus disease 2019 (COVID-19) pandemic. Despite …
Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen
Middle East respiratory syndrome coronavirus (MERS-CoV) is a lineage C betacoronavirus
that since its emergence in 2012 has caused outbreaks in human populations with case …
that since its emergence in 2012 has caused outbreaks in human populations with case …
[HTML][HTML] Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus
Respiratory syncytial virus (RSV) is a worldwide public health concern for which no vaccine
is available. Elucidation of the prefusion structure of the RSV F glycoprotein and its …
is available. Elucidation of the prefusion structure of the RSV F glycoprotein and its …